Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 27;7(12):2884-2887.
doi: 10.1182/bloodadvances.2022008990.

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

Constantine S Tam  1 , Judith Trotman  2   3 , Stephen Opat  4   5 , Jennifer C Stern  6 , Heather Allewelt  6 , Kunthel By  6 , William Novotny  6 , Jane Huang  6 , Alessandra Tedeschi  7
Affiliations

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia

Constantine S Tam et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: C.S.T. reports honoraria and institutional research funding from BeiGene, Janssen, and AbbVie. J.T. reports institutional research funding from BeiGene (for this study), Bristol Myers Squibb (BMS), Roche, PCYC, Takeda, Janssen, and Cellectar (outside of this work). S.O. has acted as a consultant/advisor for AbbVie, BeiGene, Janssen, Gilead, Roche, Mundipharma, Merck, and BMS; has received research funding from AbbVie, BeiGene, Janssen, Gilead, Roche, and Epizyme; and has received honoraria from AbbVie, BeiGene, Janssen, Gilead, Roche, Merck, and BMS. J.C.S., H.A., W.N., and J.H. are employees of and own stock in BeiGene. K.B. is an employee of BeiGene. A.T. reports serving on advisory boards and speaker bureaus for AbbVie, Janssen Spa, AstraZeneca, and BeiGene.

Figures

Figure 1.
Figure 1.
Swimmer plot of treatment duration and investigator-assessed response. BID, twice daily; CR, complete response; PD, progressive disease; PR, partial response; QD, once daily; SD, stable disease.
See this image and copyright information in PMC

References

    1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459. - PubMed
    1. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733–740. - PubMed
    1. National Comprehensive Cancer Network. National Clinical Practice Guidelines in Oncology Hairy cell leukemia. Version 1.2022. 2022. https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf - PubMed
    1. Paillassa J, Troussard X. Patients with relapsed/refractory hairy-cell leukemia. Cancer Rep (Hoboken) 2022;5(3) - PMC - PubMed
    1. Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851–859. - PMC - PubMed

Publication types

MeSH terms